

United States District Court
Northern District of California

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

UNITED STATES DISTRICT COURT
NORTHERN DISTRICT OF CALIFORNIA

PLEXXIKON INC.,
Plaintiff,
v.
NOVARTIS PHARMACEUTICALS
CORPORATION,
Defendant.

Case No. [17-cv-04405-HSG](#)

ORDER GRANTING IN PART AND DENYING IN PART MOTION TO STRIKE DEFENDANT’S DAUBERT MOTIONS

Re: Dkt. No. 236

Pending before the Court is Plaintiff Plexxikon Inc.’s motion to strike Defendant Novartis Pharmaceutical Corporation’s Daubert motions. See Dkt. No. 236. The Court held a hearing on November 1, 2019. Dkt. No. 337. As indicated during the hearing, and as detailed further below, the Court **GRANTS IN PART** and **DENIES IN PART** the motion.

I. DISCUSSION

Plaintiff challenges the timeliness of Defendant’s four Daubert motions, filed on June 6, 2019. See Dkt. Nos. 200, 202, 204, 206. In the alternative, Plaintiff seeks to strike a declaration filed in support of one of the Daubert motions. See Dkt. No. 200-1. The Court addresses each argument in turn.

A. Motion to Strike Daubert Motions for Timeliness

Plaintiff first seeks to strike all of Defendant’s Daubert motions as untimely. See Dkt. No. 236. In doing so, Plaintiff invokes the Court’s inherent authority to manage its docket. See, e.g., *Landis v. N. Am. Co.*, 299 U.S. 248, 254 (1936) (recognizing the power “inherent in every court to control the disposition of the causes on its docket with economy of time and effort for itself, for counsel, and for litigants”). Plaintiff urges that Defendant’s June 6 Daubert motions contravene at least three of the Court’s prior orders and the Court’s Civil Pretrial and Trial Standing Order.

1 On June 20, 2018, the Court issued a revised scheduling order setting the deadline for
2 hearing dispositive motions as June 20, 2019, and setting trial to begin on October 7, 2019. See
3 Dkt. No. 80. The schedule did not include a deadline for non-dispositive motions generally, or
4 Daubert motions more specifically. *Id.* On May 21, 2019, the Court directed Defendant to file its
5 dispositive motion by May 23, 2019, and continued the hearing on the parties’ dispositive
6 motions. See Dkt. No. 173. Again, the order was silent as to the timing of non-dispositive
7 motions. On May 28, 2019, the Court granted Plaintiff’s motion to extend its time to respond to
8 Defendant’s pending motions. See Dkt. No. 183. The order adopted Plaintiff’s proposal—and
9 language—to extend Plaintiff’s deadline to file oppositions to Defendant’s “dispositive and non-
10 dispositive motions,” as well as the corresponding reply deadline. *Id.*; see also Dkt. No. 180-6
11 (Proposed Order). The order also continued the hearing on the non-dispositive motions to August
12 29, 2019. See *id.* The order did not set a deadline for the filing of further non-dispositive motions.
13 Indeed, none of these orders set a non-dispositive motion or Daubert motion deadline.

14 The Court’s Civil Pretrial and Trial Standing Order states that “[m]otions in limine cannot
15 be used to request summary judgment or raise Daubert challenges unless the Court has
16 specifically granted prior approval.” See Civil Pretrial and Trial Standing Order ¶ 24. The Court’s
17 general practice is to hear Daubert motions on or before the dispositive motions hearing deadline.
18 However, the Court acknowledges that there is ambiguity in its standing order regarding when to
19 file Daubert motions. The Court will not penalize Defendant based on a non-explicit deadline,
20 particularly here where Plaintiff had ample time to oppose and argue the merits of Defendant’s
21 Daubert motions. The Court **DENIES** Plaintiff’s motion to strike Defendant’s Daubert motions
22 on this basis.

23 **B. Motion to Strike Expert Declaration**

24 One of Defendant’s June 6 Daubert motions, directed to the opinions of Plaintiff’s expert
25 Dr. Michael L. Metzker, was supported by a declaration from Defendant’s expert, Dr. Phil Baran.
26 See Dkt. No. 199-6. Plaintiff seeks, in the alternative, to strike Dr. Baran’s declaration in its
27 entirety as an untimely supplemental expert report. See Dkt. No. 236 at 4.

28 Federal Rule of Civil Procedure 26 requires that a party’s expert witness disclose, in a

1 written report, “a complete statement of all opinions the witness will express” at trial, and the
2 basis and reasons for them. See Fed. R. Civ. P. 26(a)(2)(B)(i). Rebuttal disclosures of expert
3 testimony are “intended solely to contradict or rebut evidence on the same subject matter
4 identified by another party” in its expert disclosures. See Fed. R. Civ. P. 26(a)(2)(D)(ii). Rule 26
5 further provides that these disclosures be made at the times directed by the Court. See Fed. R.
6 Civ. P. 26(a)(2)(D). Rule 37, in turn, provides that if a party fails to provide the information
7 required by Rule 26(a), “the party is not allowed to use that information or witness to supply
8 evidence on a motion, at a hearing, or at a trial, unless the failure was substantially justified or
9 harmless.” Fed. R. Civ. P. 37(c)(1). The Court has “particularly wide latitude . . . to issue
10 sanctions under Rule 37(c)(1).” *Yeti by Molly, Ltd. v. Deckers Outdoor Corp.*, 259 F.3d 1101,
11 1106 (9th Cir. 2001).

12 Here, Defendant acknowledges that Dr. Baran’s declaration contains some arguments and
13 analysis not previously disclosed in his rebuttal report. See, e.g., Dkt. No. 247 at 7, 9–12.
14 Defendant also appears to acknowledge—as it must—that Dr. Baran’s declaration was submitted
15 after the close of expert discovery. See Dkt. No. 80 (setting May 2, 2019, as the deadline for
16 expert discovery). However, Defendant urges that this new information was solely in response to
17 Dr. Metzker’s reply expert report, submitted on April 11, 2019, and Dr. Metzker’s deposition
18 testimony, taken on May 1, 2019. See *id.* at 7. As such, Defendant explains that Dr. Baran could
19 not have included these arguments in his March 14, 2019, rebuttal expert report. Defendant
20 contends that Dr. Baran’s declaration is thus an appropriate supplement under Rule 26(e)(2), and
21 even if the Court disagrees with this characterization, Dr. Baran’s declaration is substantially
22 justified and harmless and should not be precluded under Rule 37.

23 As the Ninth Circuit has explained, “[R]ule 26(e) creates a “duty to supplement,” but “not
24 a right” to do so. See *Luke v. Family Care & Urgent Med. Clinics*, 323 Fed. App’x 496, 500 (9th
25 Cir. 2009). The Ninth Circuit has cautioned that Rule 26(e) is not “a loophole through which a
26 party who submits partial expert witness disclosures, or who wishes to revise [its] disclosures in
27 light of [its] opponent’s challenges to the analysis and conclusions therein, can add to them to [its]
28 advantage after the court’s deadline for doing so has passed.” *Id.*; see also *Mariscal v. Graco*,

1 Inc., 52 F. Supp. 3d 973, 983–84 (N.D. Cal. 2014) (“Although Rule 26(e) obliges a party to
2 supplement or correct its disclosures upon information later acquired, this does not give license to
3 sandbag one’s opponent with claims and issues which should have been included in the expert
4 witness’ report” (quotation omitted)). The Court is particularly alert to such gamesmanship
5 where, as here, Defendant submitted the additional expert material in conjunction with its Daubert
6 motions, and only after expert discovery had closed. The supplementation requirement is only
7 intended to “correct[] inaccuracies, or fill[] the interstices of an incomplete report based on
8 information that was not available at the time of the initial disclosure.”¹ Id. (quotation omitted).

9 The Court, therefore, looks closely at Dr. Baran’s declaration to determine what additions
10 are derived from new information contained in Dr. Metzker’s reply report and his deposition. At a
11 high level, Dr. Baran’s declaration, much like his rebuttal report, seeks to explain why Dr.
12 Metzker’s education and experience are insufficient to qualify him as a person of ordinary skill in
13 the art (“POSITA”) in this case. Compare Dkt. No. 236-2, Ex. 1 (“Baran Rebuttal Report”), with
14 Dkt. No. 200-1 (“Baran Decl.”). But Dr. Baran’s declaration goes much further: the five
15 paragraphs in his rebuttal report about whether Dr. Metzker is a POSITA expand to 60 paragraphs
16 in his declaration. Id. The Court finds that only some of these paragraphs contain a reasonable
17 synthesis of the arguments in Dr. Baran’s rebuttal report or turn on newly supplied information.

18 Plaintiff appears to concede in reply, and the Court finds, that ¶¶ 1–32 of Dr. Baran’s
19 declaration do not contain new analysis, but rather summarize the background sections of his
20 rebuttal expert report. See Baran Decl. at ¶¶ 1–32 (describing Dr. Baran’s qualifications, a
21 summary of the asserted patents, his description of the pertinent art and a POSITA, and a
22 recitation of Dr. Metzker’s qualifications).

23 In contrast, ¶¶ 33–35 and ¶¶ 42–46 expand Dr. Baran’s prior analysis of Dr. Metzker’s
24 education and experience. See Baran Decl. at ¶¶ 33–35, 42–46. Dr. Baran cites several of Dr.

25

26 ¹ The Ninth Circuit has enumerated several factors to guide the Court’s analysis, including:
27 “(1) prejudice or surprise to the party against whom the evidence is offered; (2) the ability of that
28 party to cure the prejudice; (3) the likelihood of disruption of the trial; and (4) bad faith or
willfulness involved in not timely disclosing the evidence.” See Lanard Toys Ltd. v. Novelty, Inc.,
375 Fed. App’x 705, 713 (9th Cir. 2010). And although not binding authority, the Court considers
the Ninth Circuit’s decision in Lanard Toys as persuasive authority.

1 Metzker’s publications to conclude that a third-party, and not Dr. Metzker, performed the relevant
2 work, and that Dr. Metzker is not a POSITA. See *id.* at ¶¶ 35, 45–46. He also parses Dr.
3 Metzker’s postgraduate experience to conclude it is irrelevant or insufficient. Yet Dr. Metzker’s
4 CV and publications were available to Dr. Baran at the time he drafted his rebuttal report.

5 Moreover, ¶¶ 40, 50–57 explain the differences between Dr. Metzker’s background and
6 what Dr. Baran defines as the pertinent arts. See *id.* at ¶¶ 40, 50–57 (contrasting use of DNA
7 sequencing technology, biochemistry, and biophysics with medicinal chemistry and synthetic
8 organic chemistry). Defendant suggests that it did not know such detail would be necessary until
9 Dr. Metzker explained in reply and deposition that his experience was “equivalent” to the parties’
10 agreed-upon definition of a POSITA. See Dkt. No. 247 at 11–12. However, Defendant was on
11 notice as early as February 4, 2019, that Plaintiff intended to offer Dr. Metzker as an expert in this
12 case. See Dkt. No. 80 (setting February 4 as date for exchange of opening expert reports). The
13 Court is not persuaded that Defendant “could not have known” that Dr. Metzker would conclude
14 his background was sufficient to qualify as a POSITA until after Dr. Metzker’s deposition. See
15 Dkt. No. 247 at 11. Dr. Baran could have reviewed Dr. Metzker’s CV and explained in similar
16 detail in his rebuttal report why Dr. Metzker’s B.S. in Biochemistry and Biophysics and his Ph.D.
17 in Molecular and Human Genetics do not qualify him as a POSITA in this case. Instead, Dr.
18 Baran waited to include this detail in a declaration attached to a Daubert motion to exclude Dr.
19 Metzker. This is precisely the kind of invocation of Rule 26(e) against which the Ninth Circuit
20 has cautioned. See *Luke*, 323 Fed. App’x at 500. Likewise, the Court is not persuaded that the
21 inclusion of these paragraphs is “substantially justified.” Dr. Baran could have proffered more in-
22 depth analysis of Dr. Metzker’s background in his rebuttal report and chose not to do so.

23 The only two paragraphs in Dr. Baran’s declaration that appear to turn on new information
24 contained in Dr. Metzker’s deposition are ¶¶ 41 and 47. Paragraph 41 states that Dr. Metzker
25 testified that he supervised a postdoctoral chemist during his time as an adjunct professor, and Dr.
26 Baran concludes that supervising a chemist is not the same as actually having experience in
27 organic or medicinal chemistry. And ¶ 47 states that during his deposition, Dr. Metzker could not
28 point to any particular compound that he developed. The Court is cognizant that if an expert’s

1 subsequent reply report or deposition could always be used as a justification to supplement
2 existing expert reports, then the Court’s expert discovery deadlines would be rendered merely
3 advisory. Neither the Federal Rules nor the Court’s scheduling order contemplate preparation of
4 expert reports in perpetuity. Still, the Court agrees that Dr. Baran could not have obtained this
5 information about Dr. Metzker’s experience, or lack thereof, simply by reviewing Dr. Metzker’s
6 CV. The Court finds that these two paragraphs are thus appropriate supplementation under Rule
7 26(e).

8 Defendant argues that regardless, Dr. Baran’s declaration is harmless because Plaintiff had
9 the opportunity to respond to it in its opposition to the Daubert motion, and Plaintiff could have
10 taken Dr. Baran’s deposition about these new topics. See Dkt. No. 247 at 12–13. However,
11 Defendant ignores that expert discovery had closed on May 2, 2019, over a month before Dr.
12 Baran’s declaration was filed. See Dkt. No. 80. And although the Court ultimately continued the
13 dispositive hearing and trial dates to accommodate the complexity of this case and volume of the
14 parties’ disputes, this was not an invitation to expand discovery. As Defendant points out,
15 “whether Dr. Metzker should be able to offer his opinion to the jury [] is extremely
16 important” See Dkt. No. 247 at 13. As such, if the Court were to authorize Dr. Baran’s
17 untimely supplementation, the Court would have to substantially modify the case schedule to
18 reopen discovery on the eve of trial. The Court declines to do so, particularly as the Court has
19 already had to modify the case schedule significantly. The Court finds that Defendant will not be
20 unduly prejudiced by the exclusion because it may continue to rely on Dr. Baran’s rebuttal report
21 and several paragraphs in Dr. Baran’s declaration. Moreover, should Dr. Metzker testify at trial,
22 Defendant will have the opportunity to challenge Dr. Metzker’s qualifications at that point.

23 The Court, therefore, **GRANTS IN PART** the motion to strike Dr. Baran’s declaration,
24 finding that the untimely disclosure of the additional information contained in ¶¶ 33–35, 38–40,
25 42–46, and 50–57 was not substantially justified or harmless.

26 **II. CONCLUSION**

27 Accordingly, the Court **DENIES** Plaintiff’s motion to strike Defendant’s Daubert motions
28 as untimely, but **GRANTS IN PART** the motion to strike ¶¶ 33–35, 38–40, 42–46, 50–57 of Dr.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

Baran's declaration.

IT IS SO ORDERED.

Dated: 3/20/2020


HAYWOOD S. GILLIAM, JR.
United States District Judge